Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation parameters. The purpose of this study is to investigate the efficacy and safety of Zilucoplan in im...

Descripción completa

Detalles Bibliográficos
Autores principales: Declercq, Jozefien, Bosteels, Cedric, Van Damme, Karel, De Leeuw, Elisabeth, Maes, Bastiaan, Vandecauter, Ans, Vermeersch, Stefanie, Delporte, Anja, Demeyere, Bénédicte, Vuylsteke, Marnik, Lalla, Marianna, Smart, Trevor, Detalle, Laurent, Bouw, René, Streffer, Johannes, Degeeter, Thibo, Vergotte, Marie, Guisez, Tanguy, Van Braeckel, Eva, Van Der Straeten, Catherine, Lambrecht, Bart N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675383/
https://www.ncbi.nlm.nih.gov/pubmed/33213529
http://dx.doi.org/10.1186/s13063-020-04884-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675383/
https://www.ncbi.nlm.nih.gov/pubmed/33213529
http://dx.doi.org/10.1186/s13063-020-04884-0

Ejemplares similares